Article

Neuroprotective implant for treatment of glaucoma in phase II trial

Author(s):

Julianne Mobilian
Conferences|ASCRS

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies. 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
Cynthia Steel, PhD, MBA, appointed as Chief Scientific Officer of The Glaucoma Research Foundation
August 14th 2025

Cynthia Steel, PhD, MBA, appointed as Chief Scientific Officer of The Glaucoma Research Foundation

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
August 14th 2025

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 14th 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
August 14th 2025

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Understanding the influences on molecular confirmation after genetic testing for IRDs
August 14th 2025

Q&A: Understanding the influences on molecular confirmation after genetic testing for IRDs

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI
August 14th 2025

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI

© 2025 MJH Life Sciences

All rights reserved.